Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nemtabrutinib PK Study with Itraconazole
NCT06688045Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Oct 2023
- Primary completion
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of nemtabrutinib in B cell malignancies, sponsored by Merck & Co. Primary endpoints: Area Under the Concentration-Time Curve from Time 0 to Infinity, Area Under the Concentration-Time Curve from Time 0 to Last and 5 more. Started Oct 2023; status: completed.
02
Drugs
nemtabrutinib
03
Conditions
B cell malignancies
Beyond the preview
Go deeper on NCT06688045.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06688045.